UroGen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Scotiabank Analyst Says
UroGen Pharma (NASDAQ:URGN – Free Report) had its price target hoisted by Scotiabank from $23.00 to $47.00 in a research note issued to investors on Friday morning,Benzinga reports. Scotiabank currently has a sector outperform rating on the stock. Several other equities analysts have also issued reports on the company. D. Boral Capital reiterated a “buy” […]
UroGen Pharma (NASDAQ:URGN – Free Report) had its price target hoisted by Scotiabank from $23.00 to $47.00 in a research note issued to investors on Friday morning,Benzinga reports. Scotiabank currently has a sector outperform rating on the stock. Several other equities analysts have also issued reports on the company. D. Boral Capital reiterated a “buy” […]
